<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738023</url>
  </required_header>
  <id_info>
    <org_study_id>967-2003</org_study_id>
    <nct_id>NCT00738023</nct_id>
  </id_info>
  <brief_title>Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes</brief_title>
  <official_title>Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin resistance has been implicated as the central pathogenetic feature of cardiovascular
      risk factor cluster that includes hypertension, impaired glucose tolerance, diabetes,
      dyslipidemia, and hemostatic disorders. Recent evidence suggests that increased levels of
      free fatty acids (FFA) in obese subjects is a leading candidate in the pathogenesis of
      insulin resistance (1-4). In our preliminary studies on the effect of FFA on insulin
      secretion and action (lipotoxicity), we have observed that the infusion of Intralipid/heparin
      to increase FFA ~ four-fold-baseline levels for 48 hours results in a significant and
      reproducible raise in systolic and diastolic blood pressure (BP) in obese African American
      subjects with and without diabetes. The increase in blood pressure is apparent after 12 hours
      of infusion, reaching a peak increment of 32 mm Hg in systolic and 14 mm Hg in diastolic
      pressure at 24 hours. These preliminary findings indicate that, in addition to the well-known
      effect on insulin resistance, sustained elevation of FFA results in the development of an
      acute metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The FFA-induced hypertension constitutes a useful model with which to examine disease
      mechanisms and test new therapeutic interventions to correct the different disorders
      associated with insulin resistance and metabolic syndrome. The effect of FFA on insulin
      action is well established (4-6); however, the pressor effect of FFA infusion in obese
      subjects has not been investigated. We hypothesize that observed changes in blood pressure is
      the result of acute endothelial dysfunction due to increased FFA concentration; and that
      rosiglitazone, a PPAR gamma receptor agonist, will protect against FFA-induced elevation in
      blood pressure and endothelial dysfunction in obese subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Systolic Blood Pressure During Initial Intralipid Infusion</measure>
    <time_frame>Baseline, 48 hours</time_frame>
    <description>Systolic blood pressure change from baseline during an 48-hour intralipid infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Systolic Blood Pressure During Saline Infusions</measure>
    <time_frame>48 hours</time_frame>
    <description>Systolic blood pressure change from baseline during an 48-hour normal saline infusion in obese diabetic subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Systolic Blood Pressure During Intralipid Infusion Post-rosiglitazone Intervention</measure>
    <time_frame>48 hours</time_frame>
    <description>Systolic blood pressure change from baseline during an 48-hour intralipid infusion after taking rosiglitazone for 6 weeks in obese diabetic subjects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Diabetics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obese, normotensive African-Americans with diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours, then normal saline 0.9% at 40 ml/hr intravenously for 48 hours, and then randomized to rosiglitazone for six weeks followed by Intralipid 20% at 40ml/hr intravenously for 48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Diabetic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obese, normotensive African-Americans without diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <description>Diabetic subjects will be receive rosiglitazone for 6 weeks</description>
    <arm_group_label>Diabetics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline 0.9%</intervention_name>
    <description>Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours</description>
    <arm_group_label>Diabetics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid 20%</intervention_name>
    <description>Intralipid 20% at 40ml/hr intravenously for 48 hours</description>
    <arm_group_label>Diabetics</arm_group_label>
    <arm_group_label>Non-Diabetic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females between the ages of 18 and 70 years.

          -  Subjects must have a BMI of ≥ 30 kg/m2.

          -  Subjects must have a BP &lt; 130/80 mm Hg and no prior history of hypertension.

          -  A known history of type 2 diabetes mellitus &lt; 3 years (now 5 years).

          -  Subjects must have an HbA1c of &lt; 9%.

          -  Diabetic subjects must have been receiving as their only current anti-diabetic therapy
             stable doses of sulfonylureas for the last 2 months.

          -  Subjects must be able to understand and willing to adhere to the study protocol.

        Exclusion Criteria:

          -  Subjects with history of hypertension (BP &gt; 140/90 mm HG) or who have received
             antihypertensive drug therapy prior to the study.

          -  Obese nondiabetic controls with impaired glucose tolerance (2-hour glucose between 140
             - 199 mg/dl) during a 75-g OGTT.

          -  Diabetic subjects who require insulin therapy or have received an insulin sensitizer
             agent (metformin, rosiglitazone, pioglitazone) within 3 months of entering the study
             (at SV1, week-2).

          -  Subjects with fasting triglyceride levels &gt; 250 mg/dL prior to the study (at SV1,
             week-2).

          -  Clinically relevant hepatic disease (ALT 2.5x &gt; upper limit of normal), or other
             significant medical or surgical illness.

          -  Renal failure, as shown by a serum creatinine ≥1.5 mg/dL for males, or ≥ 1.4 mg/dL for
             females.

          -  Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study.

          -  Female subjects are pregnant or breast feeding at time of enrollment into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <results_first_submitted>December 18, 2014</results_first_submitted>
  <results_first_submitted_qc>December 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2014</results_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>diabetes,</keyword>
  <keyword>hypertension,</keyword>
  <keyword>free-fatty acids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Four subjects were withdrawn due to exclusion criteria prior to randomization. Non-diabetic arm did not continue after the first intralipid infusion (period 1).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Diabetics</title>
          <description>Obese, normotensive African-Americans with diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours, normal saline 0.9% at 40 ml/hr intravenously for 48 hours, and rosiglitazone for six weeks followed by Intralipid 20% at 40ml/hr intravenously for 48 hours</description>
        </group>
        <group group_id="P2">
          <title>Non-Diabetic</title>
          <description>Obese, normotensive African-Americans without diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intralipid Infusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Saline Infusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intralipid Infusion (Post 6 Wks of Drug)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diabetics</title>
          <description>Obese, normotensive African-Americans with diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours, normal saline 0.9% at 40 ml/hr intravenously for 48 hours, and rosiglitazone for 6 weeks followed by Intralipid 20% at 40ml/hr intravenously for 48 hours</description>
        </group>
        <group group_id="B2">
          <title>Non-Diabetic</title>
          <description>Obese, normotensive African-Americans without diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours and normal saline 0.9% at 40 ml/hr intravenously for 48 hours</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="2"/>
                    <measurement group_id="B2" value="42" spread="1"/>
                    <measurement group_id="B3" value="41.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Systolic Blood Pressure During Initial Intralipid Infusion</title>
        <description>Systolic blood pressure change from baseline during an 48-hour intralipid infusion</description>
        <time_frame>Baseline, 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diabetics</title>
            <description>Obese, normotensive African-Americans with diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours, normal saline 0.9% at 40 ml/hr intravenously for 48 hours, and rosiglitazone for 6 weeks followed by Intralipid 20% at 40ml/hr intravenously for 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Non-Diabetic</title>
            <description>Obese, normotensive African-Americans without diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours and normal saline 0.9% at 40 ml/hr intravenously for 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Systolic Blood Pressure During Initial Intralipid Infusion</title>
          <description>Systolic blood pressure change from baseline during an 48-hour intralipid infusion</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="9"/>
                    <measurement group_id="O2" value="13" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Systolic Blood Pressure During Saline Infusions</title>
        <description>Systolic blood pressure change from baseline during an 48-hour normal saline infusion in obese diabetic subjects</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diabetics</title>
            <description>Obese, normotensive African-Americans with diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours, then normal saline 0.9% at 40 ml/hr intravenously for 48 hours, and then randomized to rosiglitazone for six weeks followed by Intralipid 20% at 40ml/hr intravenously for 48 hours
Rosiglitazone: Diabetic subjects will be receive rosiglitazone for 6 weeks
Normal saline 0.9%: Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours
Intralipid 20%: Intralipid 20% at 40ml/hr intravenously for 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Systolic Blood Pressure During Saline Infusions</title>
          <description>Systolic blood pressure change from baseline during an 48-hour normal saline infusion in obese diabetic subjects</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Systolic Blood Pressure During Intralipid Infusion Post-rosiglitazone Intervention</title>
        <description>Systolic blood pressure change from baseline during an 48-hour intralipid infusion after taking rosiglitazone for 6 weeks in obese diabetic subjects</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diabetics</title>
            <description>Obese, normotensive African-Americans with diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours, then normal saline 0.9% at 40 ml/hr intravenously for 48 hours, and then randomized to rosiglitazone for six weeks followed by Intralipid 20% at 40ml/hr intravenously for 48 hours
Rosiglitazone: Diabetic subjects will be receive rosiglitazone for 6 weeks
Normal saline 0.9%: Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours
Intralipid 20%: Intralipid 20% at 40ml/hr intravenously for 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Systolic Blood Pressure During Intralipid Infusion Post-rosiglitazone Intervention</title>
          <description>Systolic blood pressure change from baseline during an 48-hour intralipid infusion after taking rosiglitazone for 6 weeks in obese diabetic subjects</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Diabetics</title>
          <description>Obese, normotensive African-Americans with diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours, normal saline 0.9% at 40 ml/hr intravenously for 48 hours, and rosiglitazone for six weeks followed by Intralipid 20% at 40ml/hr intravenously for 48 hours</description>
        </group>
        <group group_id="E2">
          <title>Non-Diabetic</title>
          <description>Obese, normotensive African-Americans without diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>pain at IV site</sub_title>
                <description>mild irritation of the vein at the infusion site for intralipid</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Guillermo Umpierrez</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-1665</phone>
      <email>geumpie@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

